Abstract
Rivaroxaban is currently the only new oral anticoagulant available for the treatment of venous thromboembolism (VTE). Comprehensive analysis of the study data EINSTEIN-DVT and EINSTEIN-PE evaluation 8282 patients showed comparable treatment effect and also significantly reduced the risk of major bleeding in patients treated with rivaroxaban compared with warfarin.
Also, treatment of patients with cancer were equally effective and safe to use with patients without cancer. The treatment with rivaroxaban should also benefit patients with increased bleeding risk: patients weighing less than 50 kg, 75 years of age and patients with renal insufficiency (glomerular filtration rate from 0.5 to 0.8 ml / s).
The extent of thrombosis or pulmonary embolism did not influence the effect of treatment with rivaroxaban. Rivaroxaban is thus a drug with a very favorable effect on a broad spectrum of patients with TEN.